accelerated approval

Stock decreasing graphic

Biotech

Applied Tx's stock drops on non-update for rare disease asset

The biotech’s stock has fallen nearly 50% from its previous close of $1.24 per share, currently resting at $0.66 as of 10:45 a.m. ET this morning.

Gabrielle Masson Sep 29, 2025 10:57am

road through forest

Fierce Pharma

Stealth scores FDA approval for 1st Barth syndrome treatment

Sep 19, 2025 6:00pm

image of two race cars neck and neck

Daiichi, Merck rev up for accelerated approval filing

Sep 7, 2025 10:45am

clock delay wait time alarm

Regenxbio's Hunter gene therapy latest to face FDA delay

Aug 19, 2025 10:30am

Fabry disease

Cash-strapped Sangamo seeks partner for new gene therapy

Jun 24, 2025 11:53am

rare diseases

Stealth CEO questions FDA rejection of rare disease drug

May 29, 2025 2:27pm